Patents by Inventor Lance E. Steward

Lance E. Steward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibiting Aberrant Blood Vessel Formation Using Growth Factor Retargeted Endopeptidases
    Publication number: 20120207704
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal using such TVEMP compositions.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 16, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Joseph Francis, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt, Kei Roger Aoki, Ester Fernandez-Salas
  • Modified Clostridial Toxins with Enhanced Targeting Capabilities For Endogenous Clostridial Toxin Receptor Systems
    Publication number: 20120178140
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: February 27, 2012
    Publication date: July 12, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Leucine-based motif and clostridial neurotoxins
    Patent number: 8206723
    Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: June 26, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Todd M. Herrington, Kei Roger Aoki
  • NEUROTOXINS WITH ENHANCED TARGET SPECIFICITY
    Publication number: 20120135495
    Abstract: Modified neurotoxins that contain protease cleavage sites susceptible uniquely to proteases present in certain tissues are described. The toxins can be selectively activated by proteases in muscle or selectively inactivated by proteases in blood.
    Type: Application
    Filed: September 18, 2008
    Publication date: May 31, 2012
    Applicant: Allergan, Inc.
    Inventors: WEI-JEN LIN, Kei Roger Aoki, Lance E. Steward
  • Botulinum Neurotoxin Serotype B Activatable Botulinum Neurotoxin Serotype Bs
    Publication number: 20120115205
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located in the di-chain loop region; and method of producing modified Clostridial toxins comprising Clostridial toxin substrate cleavage site located within the di-chain loop region.
    Type: Application
    Filed: August 30, 2010
    Publication date: May 10, 2012
    Applicant: ALLERGAN, INC.
    Inventors: LANCE E. STEWARD, MELVIN S. OKA
  • Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
    Patent number: 8128940
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: March 6, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei R. Aoki
  • Modified Clostridial Toxins with Altered Targeting Capabilities For Clostridial Toxin Target Cells
    Publication number: 20120052548
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: October 26, 2011
    Publication date: March 1, 2012
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Lipophilic dye-based fret assays for clostridal toxin activity
    Patent number: 8124357
    Abstract: Compositions useful for detecting Clostridial toxin activity comprising a cell that comprises a membrane-associated Clostridial toxin substrate comprising a first member of a fluorescence resonance energy transfer pair; and a Clostridial toxin recognition sequence including a cleavage site; and a membrane-associated second member of the FRET pair and methods useful for determining Clostridial toxin activity using such Clostridial toxin substrates.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: February 28, 2012
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki
  • Post-translational modifications and clostridial neurotoxins
    Patent number: 8119767
    Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: February 21, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Athena Spanoyannis, K. Roger Aoki, Wei-Jen Lin
  • Activatable clostridial toxins
    Patent number: 8071110
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: December 6, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20110294742
    Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
    Type: Application
    Filed: August 15, 2011
    Publication date: December 1, 2011
    Applicant: ALLERGAN, INC.
    Inventors: LANCE E. STEWARD, ESTER G. FERNANDEZ-SALAS, MARCELLA A. GILMORE, JOSEPH FRANCIS, SHENGWEN LI, KEI ROGER AOKI
  • Clostridial toxin activity assays
    Patent number: 8067231
    Abstract: Compositions useful for detecting Clostridial toxin activity comprising a cell that contains an exogenous Clostridial toxin substrate which comprises a fluorescent member, a membrane targeting domain and a Clostridial toxin recognition sequence comprising a cleavage site, where the cleavage site intervenes between the fluorescent member and the membrane targeting domain; and methods useful for determining Clostridial toxin activity using such Clostridial toxin substrates.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: November 29, 2011
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki
  • Degradable Clostridial Toxins
    Publication number: 20110287517
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: May 20, 2011
    Publication date: November 24, 2011
    Applicant: ALLERGAN, INC.
    Inventors: LANCE E. STEWARD, SANJIV GHANSHANI, ESTER FERNANDEZ-SALAS, MARCELLA A. GILMORE, JOSEPH FRANCIS, KEI ROGER AOKI
  • FRET protease assays for clostridial toxins
    Patent number: 8053208
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: November 8, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • FRET protease assays for clostridial toxins
    Patent number: 8053209
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: November 8, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
    Patent number: 8052979
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: November 8, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • FRET protease assays for clostridial toxins
    Patent number: 8048643
    Abstract: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence that includes a cleavage site, where the cleavage site intervenes between the donor fluorophore and the acceptor and where, under the appropriate conditions, resonance energy transfer is exhibited between the donor fluorophore and the acceptor.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: November 1, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Kei Roger Aoki
  • Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
    Patent number: 8022172
    Abstract: Clostridial toxin substrates comprising a lanthanide donor complex, an acceptor, and a Clostridial toxin recognition sequence including a cleavage site; methods for determining the activity of a Clostridial toxin from a test sample using such Clostridial toxin substrates; cell compositions comprising such Clostridial toxin substrates and a Clostridial toxin receptor; and methods for determining the activity of a Clostridial toxin from a test sample using such cell compositions.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: September 20, 2011
    Assignee: Allergan, Inc.
    Inventors: Dudley J. Williams, Marcella A. Gilmore, Lance E. Steward, Marc Verhagen, Kei Roger Aoki, Ester Fernandez-Salas
  • Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
    Patent number: 8021859
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: September 20, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Chimera botulinum toxin type E
    Patent number: 8017741
    Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: September 13, 2011
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki